Related by context. All words. (Click for frequent words.) 71 ThermoDox ® clinical 70 Phase Ib II 68 Phase #b/#a clinical 67 website http:/www.celsion.com 66 ThermoDox R 66 website www.celsion.com 66 Phase IIIb clinical 66 fidaxomicin Phase 66 APEX PD 66 BRIM3 65 ENDEAVOR III 65 Initiates Phase II 65 NSABP B 65 NCIC CTG 65 phase IIa clinical 65 ALN VSP Phase 65 Completes Patient Enrollment 65 Phase Ib clinical 65 MEND CABG II 65 BRIM2 65 randomized Phase 2b 64 Phase 1a clinical 64 MERLIN TIMI 64 Phase III HEAT 64 oral ridaforolimus 64 Phase IIb III 64 NO# [002] 64 randomized controlled multicenter 64 initiated Phase Ib 64 Bayer HealthCare Onyx Pharmaceuticals 64 Phase III ADT 64 Pivotal Phase III 64 TNFerade TM 64 ALSYMPCA 64 Phase III Pivotal 64 Combination REOLYSIN R 64 Phase 2b kidney transplant 64 evaluating Actimmune 64 SPIRIT FIRST 64 multicenter Phase II 64 randomized controlled Phase 64 MAGE A3 ASCI 64 Randomized Evaluation 64 number NCT# ClinicalTrials.gov 64 placebo controlled Phase III 64 CHAMPION PCI 64 PRECISE trial 63 XL# SAR# 63 EXPLORE Xa 63 phase IIIb 63 Phase Ib IIa 63 SUCCEED trial 63 Cloretazine ® 63 CATIE AD 63 APPRAISE 63 Quinamed 63 Prostate AdenoCarcinoma Treatment 63 HDL Selective Delipidation 63 PERSEUS clinical program 63 Completes Dosing 63 candidate CRLX# 63 ongoing Phase 1b 63 Hepatocellular Carcinoma 63 Initiate Phase II 63 TG MV 63 Zemplar Capsules 63 ThermoDox ® 63 Phase III multicenter 63 phase IIb trial 63 Pivotal Phase 63 FOLOTYN ® 63 TASKi2 63 multicenter phase 63 ENDEAVOR IV 63 EURIDIS 63 MIST II 63 AVOREN 62 MGd 62 LUX Lung 62 ENLIGHT 62 evaluating mipomersen 62 Submits NDA 62 PROTECT AF 62 BR.# 62 neratinib 62 PFO migraine 62 Metastatic Melanoma 62 Randomized Phase II 62 Initiates Phase III 62 Initiates Clinical 62 phase Ib 62 Zenvia Phase III 62 ORAL Sync 62 phase IIb 62 REMINYL ® 62 Begins Dosing 62 HORIZONS AMI 62 Initiated Phase 62 www.celsion.com 62 placebo controlled clinical 62 Initiates Enrollment 62 CAPRIE 62 RELOVAIR ™ 62 initiated Phase 1b 62 elotuzumab 62 novel oral anticoagulant 61 Initiate Phase 61 Urocortin 2 61 relapsed MM 61 ORACLE MS 61 Initiates Phase 2b 61 BCIRG 61 evaluating satraplatin 61 phase IIb clinical 61 GERD migraine headaches 61 Phase 2b Clinical Trial 61 Phase III placebo controlled 61 confirmatory pivotal 61 assessing T DM1 61 ENESTnd 61 Randomized controlled 61 alvespimycin 61 metastatic hormone refractory 61 pivotal bioequivalence 61 Cloretazine 61 IMPACT DCM 61 First Patient Enrolled 61 Phase III psoriasis 61 PERSEUS 61 forodesine 61 PrevOnco ™ 61 Phase 2a preventative 61 rALLy clinical trial 61 Clinical Trial Results 61 ADVANCE PD 61 MEND CABG 61 Matrix Phase 2b 61 ID NCT# 61 Phase Ib study 61 randomized discontinuation 61 multicenter randomized controlled 61 IIb clinical trial 61 Deforolimus 61 Delcath Phase III 61 Successfully Completes Phase 61 Initiates Clinical Trial 61 prospective multicenter randomized 61 Phase 1b dose escalation 61 Selective Electrochemical Tumor Ablation 61 Demonstrates Significant 61 CVac 61 randomized multicenter Phase III 61 Pivotal Trial 61 randomized Phase IIb 61 lorcaserin Phase 61 placebo controlled Phase 61 initiate Phase IIb 61 multicenter randomized Phase 61 CCR5 mAb 61 www.ClinicalTrials.gov 61 Completes Enrollment 61 relapsed refractory multiple myeloma 61 Cimzia TM 61 PANVAC VF 61 Phase #b/#a 61 Phase III Clinical Trial 61 registrational Phase 61 Clinical Antipsychotic Trials 61 confirmatory clinical 61 Phase lll 60 Clinical Trial Data 60 Aplidin R 60 trastuzumab DM1 T DM1 60 refractory chronic lymphocytic 60 LibiGel Phase III 60 PRE SURGE 60 Meets Primary Endpoint 60 Severe Sepsis 60 PROVENGE ® 60 Panzem NCD 60 reslizumab 60 RE SURGE 60 phase IIb III 60 CLARITY TIMI 60 PI3K/Akt pathway inhibitor 60 CONQUER OB 60 lexidronam injection 60 Truvada tablets 60 seliciclib CYC# 60 CARE HF 60 Nexavar prescribing 60 Allovectin 7 60 Phase 1b trial 60 ABSORB clinical 60 compound INCB# 60 Intervention Effectiveness 60 Presents Preclinical 60 blinded randomized placebo controlled 60 GAMMAGARD 60 APEX AMI trial 60 Dual Opioid 60 Archexin 60 RCW breast cancer 60 Azedra 60 fosbretabulin 60 interferon gamma 1b 60 STRIDE PD 60 MAA submission 60 Phase IIB 60 IMPACT IMmunotherapy 60 PrevOnco 60 RE LY ® 60 GOUT 60 Anturol TM 60 PDX pralatrexate 60 PF # [002] 60 PRIMO CABG2 60 Aryplase 60 AIM HIGH 60 PREOS R 60 Phase III AFFIRM 60 OvaRex ® MAb 60 ExTRACT TIMI 60 PSMA ADC 60 Clinicaltrials.gov 60 YONDELIS 60 opioid induced bowel dysfunction 60 tramiprosate Alzhemed TM 60 DermaVir Patch 60 durable pain palliation 60 inhaled AAT 60 Asentar 60 STEALTH C 60 TAXUS IV 60 please visit http:/www.sunesis.com 60 Androxal TM 60 VESTASYNC 59 CAMMS# 59 budesonide MMX 59 http:/www.clinicaltrials.gov 59 multicenter Phase III 59 randomized Phase III 59 PEG SN# 59 www.cellgenesys.com 59 Phase IIb clinical 59 ularitide 59 EVEREST II 59 Zenvia ™ 59 please visit www.advaxis.com 59 Pre RELAX AHF 59 multicenter clinical 59 Proellex TM 59 confirmatory Phase IIIb 59 Phase 2a clinical 59 evaluating satraplatin plus 59 rALLy trial 59 Phase #/#a 59 SPIRIT IV 59 REVEAL Registry 59 Advaxis Phase 59 evaluating tivozanib 59 Phase 1b clinical 59 ospemifene 59 multicentre prospective 59 Prospective Randomized 59 Initiate Clinical Trial 59 SPRYCEL ® 59 INCB# [001] 59 bepotastine besilate nasal spray 59 Presents Preclinical Data 59 initiate multicenter 59 REG2 59 Reports Preclinical Data 59 Genasense ® oblimersen 59 HGS# 59 Phase III randomized controlled 59 ToGA 59 TEMSO 59 phase IIa 59 http:/www.clinicaltrials.gov/ 59 Phase 1b clinical trials 59 orally inhaled migraine 59 sunitinib malate 59 Renal Cell Carcinoma RCC 59 IMC #B 59 ACCORD Lipid 59 Patient Enrollment 59 CALGB 59 bevirimat Study 59 Pafuramidine 59 PRECISE Trial 59 Multicenter Phase 59 dose escalation clinical 59 SUTENT ® 59 Crofelemer budesonide foam 59 Achieves Primary Endpoint 59 CRLX# 59 PRECISE 59 Files Investigational 59 R roscovitine 59 controlled multicenter Phase 59 Dyloject TM 59 Pivotal Study 59 trastuzumab emtansine T DM1 59 Xelox 59 CALERIE 59 Phase 2b Trial 59 Panzem ® 59 VITAL Trial 59 Microwave Ablation System 59 ADMIRE HF 59 PARTNER Trial 59 Advanced Melanoma 59 identifier NCT# 59 PHX# 59 ACCLAIM II 59 Eluting Stent 59 Presents Positive 59 pertuzumab 59 AFRS TM 59 Phase 1b Clinical Trial 59 EDEMA3 59 LymphoStat B TM 59 www.vivus.com 59 Glufosfamide 59 deforolimus 59 paclitaxel poliglumex 59 OLYMPIA registry 59 AVADO 59 dextromethorphan quinidine 59 Tanespimycin 59 induced macular edema 59 Tesmilifene 59 ASCO GI 59 Trastuzumab DM1 59 Genasense oblimersen sodium Injection 59 evaluating carfilzomib 59 CURRENT OASIS 7 59 pharmacokinetic PK 59 RE LY 59 ICON7 59 Multiple Ascending Dose 59 multicentre randomized 59 metastatic castration resistant 59 immunotherapeutic vaccine 59 INSPIRE Trial Phase III 59 Demonstrates Sustained 59 Phase 2a Trial 59 VALOR trial 59 NCCTG N# 59 Phase IIIb 59 prospective randomized multicenter 59 brivanib 59 www.accentia.net 59 Phase 2b clinical 59 oral picoplatin 59 CALGB # [002] 59 TELINTRA R 59 DIRECT Trial 59 SPIRIT III 59 mertansine 59 IL# PE#QQR 59 ACAPODENE 59 Tramiprosate ALZHEMED TM 59 AEGR 59 Acute Ischemic Stroke 59 phase IIb study 59 CLIRS trial 59 treatment naive genotype 58 Aggressive Reduction 58 brivaracetam 58 rALLy 58 Phase III Trial 58 dirucotide MBP# 58 HDAC Inhibitor 58 sorafenib tablets 58 ZACTIMA 58 including eniluracil ADH 58 relapsing multiple sclerosis 58 Carotid Revascularization Endarterectomy vs. 58 Refractory Angina 58 Phase IIb Clinical Trial 58 HCV SPRINT 58 ritonavir boosted danoprevir 58 multicenter prospective 58 EchoCRT 58 Temsirolimus 58 Medullary Thyroid Cancer 58 eritoran 58 phase 2a 58 lintuzumab 58 investigational immunotherapy 58 personalized cellular immunotherapy 58 PRESEPT 58 Elagolix 58 azilsartan medoxomil 58 preclinical efficacy 58 FOLFOX6 chemotherapy regimen 58 Solorel 58 budesonide foam 58 IND Filing 58 multicenter Phase 58 Phase IIb Trial 58 PROTEGE 58 IMA# 58 OLpur TM H2H 58 ONCONASE R 58 ONTARGET 58 BRAF inhibitor 58 vernakalant hydrochloride 58 Commences Phase 58 novel VDA molecule 58 Amrubicin 58 Hsp# Inhibitor 58 PROSTVAC TM 58 Panzem R 58 Oral Insulin Capsule 58 Recurrent Breast Cancer 58 relapsing remitting MS RRMS 58 please visit http:/www.atherogenics.com 58 Prolongs Survival 58 SABCS 58 CLL8 58 Randomized Phase 58 ARISE Phase III 58 Corlux 58 LungAlert TM 58 budesonide MMX Phase III 58 Personalized Immunotherapy 58 hoFH 58 sNDA submission 58 fidaxomicin Phase 3 58 Curaxin CBLC# 58 MADIT 58 sorafenib Nexavar 58 Schizophrenia Treatment 58 NDA Submission 58 RE MODEL 58 dose escalation Phase 58 Confirmatory Phase 58 viral kinetic 58 Nasdaq ACHN 58 Degarelix 58 CLIRS 58 palifosfamide Zymafos TM 58 Nasdaq CLSN 58 Virtual Histology 58 Testosterone MDTS ® 58 Clinical Trials Update 58 Lung Cancer Trial 58 Oral Calcitonin 58 initiate Phase Ib 58 preclinical pharmacokinetic 58 www.syntapharma.com 58 Alvesco R 58 ALN HPN 58 Randomized Double Blind 58 Dose Escalation 58 Study Evaluating 58 Val HeFT 58 Nasdaq DVAX 58 VNP#M 58 PLK1 SNALP 58 Intervention Effectiveness CATIE 58 trodusquemine 58 multicenter randomized clinical 58 Bezielle 58 Receives Orphan Drug Designation 58 registrational trial 58 DAPT Study 58 non resectable 58 Initiate Phase III 58 Daclizumab 58 Sunesis Pharma 58 ZOLINZA 58 Anti CD# Antibody 58 multicentre randomized controlled 58 Investigational Treatment 58 evaluating REVLIMID 58 Celsion Corporation 58 Arzerra TM 58 OPT CHF 58 pharmacokinetic PK study 58 Dacogen injection 58 tanespimycin 58 lintuzumab SGN 58 CHARM Added 58 observational cohort study 58 UPLYSO 58 ONTARGET R 58 CIMZIA TM certolizumab pegol 58 Diabetic Macular Edema 58 docetaxel Taxotere R 58 TLK# 58 oral deforolimus 58 www.vicortech.com 58 Lenocta 58 Panzem R NCD 58 NASDAQ CLSN 58 PMA submission 58 Presents Positive Preclinical 58 AIR CF1 58 Unstable Angina 58 Prednisone Against Refractory 58 JAK2 Inhibitor 58 pain palliation 57 Saforis 57 Vidaza ® 57 OvaRex R 57 Efficacy Results 57 Safinamide 57 Acute Decompensated Heart Failure 57 randomized discontinuation trial 57 Edge STudy 57 Pegylated Liposomal Doxorubicin 57 LUMINATE 57 Phase III Clinical Trials 57 Randomized Phase III 57 Alocrest 57 multicenter randomized placebo controlled 57 novel histone deacetylase 57 Allovectin 7 ® 57 ARCOXIA 57 XIENCE V Stent System 57 Multicenter Randomized 57 Oral Fingolimod 57 DUROS 57 RECORD1 57 recurrent metastatic 57 Evoltra ® 57 toenail onychomycosis 57 tesmilifene 57 pralatrexate injection folate analogue 57 telomerase inhibitor drug 57 omacetaxine mepesuccinate 57 TASKi3 57 Phase IIA 57 Protease Inhibitor 57 LibiGel ® 57 clinicaltrials 57 CIP TRAMADOL ER 57 AeroLEF TM 57 Velcade bortezomib 57 Phase IIb clinical trials 57 alemtuzumab Campath 57 AIR2 Trial 57 Efficacy Trial 57 Avastin adjuvant 57 Embolic Protection Device 57 prelicensure 57 Demonstrates Efficacy 57 systemic anaplastic large 57 NABTT 57 GetGoal Phase III 57 pharmacokinetic pharmacodynamic 57 Files IND 57 apricitabine ATC 57 thalidomide Thalomid 57 Xcytrin R 57 Lucanix 57 MKC# MKC# PP 57 Recurrent Glioblastoma 57 BrachySil TM 57 Diamyd Medical Diamyd 57 Nasdaq IDRA today 57 Immunotherapeutic 57 Ketotransdel 57 TAXUS Element Stent System 57 ARDIS 57 http:/www.vivus.com 57 IIa clinical 57 ANCHOR trial 57 GRAVITAS trial 57 please visit www.dyax.com 57 double blinded randomized 57 depsipeptide 57 EOquin TM 57 recurrent NSCLC 57 Phase 2a Clinical Trial 57 REVIVE Diabetes 57 Telatinib 57 please visit www.medicinova.com 57 dose escalation phase 57 Novel Oral 57 initiate Phase 2b 57 phase III isavuconazole 57 GATTEX TM 57 Cardiotoxicity 57 doxorubicin Transdrug ® 57 phase Ib clinical 57 landmark ATHENA 57 Granted Orphan Drug 57 www.novartis.com 57 Vitaxin 57 confirmatory Phase III 57 CEQ# 57 HCV RESPOND 2 57 vosaroxin 57 demonstrated antitumor activity 57 programs visit http:/www.bionovo.com 57 TransVax ™ 57 Evoltra 57 Brentuximab Vedotin SGN 57 AIR CF2 57 Phase 1b 57 XYOTAX TM 57 mg BID dose 57 Onconase 57 Randomized Study 57 dacarbazine chemotherapy 57 vapreotide acetate 57 HuMax EGFr 57 oxypurinol 57 Dose Ranging Study 57 sulodexide 57 GNSZ 57 Harry Palmin President 57 Biologic License Application BLA 57 Phase Forward InForm 57 initiate Phase 1b 57 PIX# [002] 57 www.paintrials.com 57 Omacetaxine 57 Zerenex ™ 57 paclitaxel Taxol R 57 LEVADEX ™ 57 CRMD# 57 Current Controlled Trials 57 Topline Results 57 XL# XL# XL# 57 www.pharsight.com 57 AVASTIN 57 Sensipar R 57 generation purine nucleoside 57 call #.#.NEXAVAR #.#.#.# 57 SNT MC# 57 satraplatin Phase 57 SYMMETRY trial 57 acyclovir Lauriad R 57 NSABP 57 Vicriviroc 57 Phase Ia Ib 57 Prestara 57 TM Drug Eluting 57 multicenter multinational 57 Viprinex TM 57 Phase IIb trials 57 Triapine R 57 CYT# potent vascular disrupting 57 GATTEX ® 57 Receives Milestone Payment 57 Hodgkin lymphoma HL 57 TOLAMBA 57 EmbraceAC 57 Phase IIB clinical 57 custirsen 57 Phase Ib 57 cisplatin gemcitabine 57 LungSign TM 57 Xanafide 57 EFAPROXYN 57 Valopicitabine 57 visit smith.com 57 recurrent malignant glioma 57 Nasdaq SNSS 57 RESTORE CLI 57 HCV Protease Inhibitor 57 Nasdaq NPSP 57 REALITY Trial 57 BrainGate TM 57 regorafenib 57 Pertuzumab 57 Second Pivotal Phase 57 Dapagliflozin 57 dependent kinase inhibitor 57 Breast Density 57 ELACYT 57 Virulizin ® 57 Genasense R oblimersen 57 neoadjuvant treatment 57 THALOMID 57 TRACON Pharmaceuticals 57 phase III ACCLAIM 57 Hepatocellular Carcinoma HCC 57 Therapy Evaluation 57 Phase IIIb study 57 recurrent metastatic ovarian cancer 57 Endeavor Drug Eluting 57 PROSTASCINT R 57 Phase III VISTA 57 recurrent glioblastoma multiforme 57 ExCell 57 Gastrointestinal Cancers Symposium 57 comparing XIENCE V 57 CoFactor 57 Sapacitabine 57 prospectively defined 57 virus HCV protease inhibitor 57 Patient Enrolment 57 TMC# C# 57 Phase 1a 57 PROMACTA CARES 57 Eluting Coronary Stent System 57 Canvaxin 57 Clinical Evaluation 56 PEGylated interferon beta 1a 56 ROCKET AF 56 ganetespib 56 Cerebril TM 56 ixabepilone 56 PD2i CA 56 R rosiglitazone maleate 56 radiation dosimetry 56 LAB CGRP 56 ASH Annual Meeting 56 GW# [003] 56 Phase Ib Clinical Trial 56 ZYBRESTAT TM 56 R lenalidomide 56 Vascular Disrupting Agent 56 evaluating bafetinib 56 somatostatin analog 56 Systemic Delivery 56 LymphoStat B belimumab 56 ThermoDox 56 COU AA 56 bicifadine 56 Asthma Intervention 56 Febuxostat 56 By JENNIFER LEARN 56 NEVO 56 adecatumumab MT# 56 non nucleoside inhibitor 56 lomitapide 56 farletuzumab 56 CERVARIX 56 Systemic Sclerosis 56 HGS ETR2 56 stated Michelle Berrey 56 midstage clinical 56 R#/MEM 56 Sipuleucel T 56 GRNVAC1 56 Tectin TM 56 Vaccine Adjuvant 56 thetreatment 56 ticagrelor Brilinta 56 BLA filing 56 Octreolin 56 novel orally inhaled 56 Virulizin R 56 Phase 2b 56 Submits Response 56 ENGAGE AF TIMI 56 liposomal formulation 56 Receives Orphan Drug 56 NASDAQ ABII 56 CA9 SCAN 56 Phase Ia 56 CINQUIL 56 www.cticseattle.com 56 novel emulsion formulation 56 AAG geldanamycin analog 56 Inhalation Solution 56 GENASIS clinical 56 Phase IIa trials 56 DEEP AF 56 confirmatory Phase 3 56 Nasdaq MITI 56 bardoxolone 56 Solorel TM 56 deCODE AF TM 56 AACR IASLC Joint 56 prospective observational cohort 56 leading oral taxane 56 multicenter randomized double 56 HuLuc# 56 Aflibercept 56 Biomarker Study 56 TMC# [002] 56 DCVax R 56 ENDEAVOR IV clinical 56 Investigational Device Exemption 56 TransVax 56 pharmacodynamic profiles 56 beta 1a 56 BrachySil ™ 56 EnteroMedics proprietary neuroblocking technology 56 Edwards SAPIEN valve 56 Neuradiab 56 JOULFERON 56 AACR #st Annual Meeting 56 Liprotamase 56 PIX# trial 56 CCX# 56 Sibutramine Cardiovascular Outcomes 56 Varespladib 56 TKB# 56 Hormone Refractory Prostate Cancer 56 www.pranabio.com 56 Pemetrexed 56 http:/www.celgene.com 56 BCLI 56 Intravenous CP 56 sarcoma melanoma 56 Percutaneous Tibial Nerve Stimulation 56 IND Application 56 CLARITY study 56 randomized multicentre 56 Tykerb lapatinib 56 radiation sensitizer 56 HCD# [002] 56 Rigel R# 56 Announces Poster Presentations 56 Decompensated Heart Failure 56 pharmacogenomic translational research 56 MEK Inhibitor 56 teriflunomide 56 Patient Registry 56 Phase 2a trial 56 Albuferon Phase 56 www.ilgenetics.com 56 Polyp Prevention Trial 56 Lomitapide 56 Deferiprone 56 SANVAR 56 RG# ITMN 56 BOLDER II 56 MoxDuo 56 GATTEX ™ 56 www.micromet inc.com 56 Bosutinib 56 ACRIN 56 Aplidin 56 NEVO RES 56 Therapeutic Competitors companiesandmarkets.com adEgemonye 56 AstraZeneca Targacept 56 SUPPRELIN R LA 56 PROactive Study 56 evaluating T DM1 56 NASDAQ IMMU 56 registrational 56 Premarket Approval PMA 56 Augment Injectable 56 RSR# 56 Raloxifene Evaluation MORE 56 Exherin TM 56 candidate XP# 56 Custom NX 56 trial evaluating PRX# 56 www.criticaloutcome.com 56 NSABP C 56 Phase IIa clinical 56 unique alkylating agent 56 Hedgehog Pathway Inhibitor 56 Medidur TM FA 56 COSTAR II 56 AKT inhibitor 56 Randomized Double blind 56 DSMB recommended 56 3 registrational trial 56 Trial PCPT 56 SNT-MC#/idebenone 56 bazedoxifene conjugated estrogens 56 AZILECT R 56 axitinib 56 aclidinium bromide 56 lead Aganocide compound 56 nasal calcitonin product 56 www.anthera.com 56 Zybrestat 56 Ceflatonin R 56 oral FTY# 56 AEG# 56 Adjuvant Treatment 56 Traficet EN 56 OMNARIS HFA 56 PNP inhibitor 56 orally administered inhibitor 56 modified glutathione analog 56 Pooled Analysis 56 www.clinicaltrials.gov 56 Myocet 56 generation URAT1 inhibitor 56 GLP1 INT TM 56 TAXUS VI 56 CIMZIA ™ 56 dimebon latrepirdine 56 Bucindolol 56 Pyridorin 56 visit http:/www.clinicaltrials.gov/ 56 Nasdaq PPHM 56 biliary tract cancer 56 Onrigin TM 56 ATACAND 56 Dacogen decitabine 56 Therapeutic Competitors 56 www.adeonapharma.com 56 Phase 2b study 56 severe hypercholesterolemia 56 MBRX 56 Clinical Trial Evaluating 56 enzastaurin 56 ChemGenex Pharmaceuticals Limited 56 prasterone 56 Acute Myocardial Infarction 56 Randomised 56 LibiGel testosterone gel 56 LSE ASM 56 confirmatory Phase 56 Cancer Incidence Mortality 56 subcutaneous formulation 56 Cerebral Amyloid Angiopathy 56 tolerability pharmacokinetics 56 Bicifadine 56 DASISION 56 Fast Tracked Phase 56 Late Breaker 56 PreCISe 56 Xeloda ® 56 www.candelalaser.com 56 IgG1 monoclonal antibody 56 #nd EORTC NCI 56 Ranolazine 56 Sirolimus eluting Coronary Stent 56 MADIT II 56 hypoxia activated prodrug 56 acyclovir Lauriad ® 56 Chronic Heart Failure 56 Gemzar ® 56 cetrorelix pamoate 56 Annamycin 56 Ridaforolimus 56 Potelligent Technology 56 Renal dysfunction 56 Vectibix panitumumab 56 RhuDex 56 Vion Pharmaceuticals 56 HQK 56 Patients Treated With 56 balsalazide tablet 56 Xcellerated T Cells 56 successfully commercialize Iluvien 56 OvaRex MAb 56 NATRECOR ® 56 Pivotal Phase II 56 recurrent glioma 56 PROPEL 56 catheter occlusion 56 EDEMA3 trial 56 pentostatin 56 Estybon ™ 56 TransVax tm 56 Celacade TM technology 56 Coronary Artery Bypass Graft 56 galiximab 56 Phase III confirmatory 56 Alnylam Nasdaq ALNY 56 FavId 56 AZD# TC 56 Diabetic Nephropathy 55 Fondaparinux 55 www.med 55 placebo controlled randomized 55 www.asco.org 55 Recurrent Chest Wall 55 Tarceva TM 55 dose escalation trial 55 LightTouch 55 bavituximab monotherapy trial 55 Sunovion Pharmaceuticals Inc. 55 Civacir 55 Screening Trial 55 pivotal Phase III 55 evaluating Vectibix 55 liposomal doxorubicin 55 clinicaltrials.gov 55 Multicenter Automatic Defibrillator Implantation 55 prospective multicentre 55 Trofex 55 Tesetaxel 55 PROVENGE sipuleucel T 55 TBC# 55 RAPTIVA 55 Phase III pivotal 55 APF# Phase 55 Hepatotoxicity 55 Squalamine 55 docetaxel Taxotere ® 55 BENICAR HCT 55 Cardioxyl Pharmaceuticals 55 PROTECT II 55 Locteron ® 55 SIMPADICO 55 BRAF mutated 55 MOZOBIL 55 torezolid phosphate 55 fallopian tube cancers 55 drug eluting stent DES